Imatinib-induced subclinical liver injury: histological changes of non-tumorous hepatic parenchyma

1. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347:472-80.10.1056/NEJMoa02046112181401Search in Google Scholar

2. Schwetz BA. New Treatment for Chronic Myelogenous Leukemia. JAMA. 2001; 286:35.10.1001/jama.286.1.3511434814Search in Google Scholar

3. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002; 8: 935-42.Search in Google Scholar

4. Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF. Imatinib (Gleevec®) induced hepatotoxicity. J Clin Gastroenterol 2005; 39:75-7.Search in Google Scholar

5. Kikuchi S, Muroi K, Takahashi S, Kawano-Yamamoto C, Takatoku M, Miyazato A, et al. Severe hepatitis and complete molecular response caused by imatinib mesylate : possible association of its serum concentration with clinical outcomes. Leuk Lymphoma. 2004; 45:2349-51.10.1080/1042819041233127272115512829Search in Google Scholar

6. Lin NU, Sarantopoulos S, Stone JR, Galinsky I, Stone RM, Deangelo DJ, et al. Fatal hepatic necrosis following imatinib mesylate therapy. Blood. 2003; 102: 3455-6.10.1182/blood-2003-07-232314568907Search in Google Scholar

7. Ohyashiki K, Kuriyama Y, Nakajima A, Tauchi T, Ito Y, Miyazawa H, et al. Imatinib mesylate-induced hepatotoxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis, Leukemia. 2002; 16:2160-1.Search in Google Scholar

8. James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia. 2003; 7:978-9.10.1038/sj.leu.240291012750713Search in Google Scholar

9. Pas TDe, Danesi R, Catania C, Curigliano G, Braud FDe. Imatinib administration in two patients with liver metastases from GIST and severe jaundice. Br J Cancer. 2003; 89:1403-4.10.1038/sj.bjc.6601282239435514562006Search in Google Scholar

10. Bauer S, Hagen V, Pielken HJ, Bojko P, Seeber S, Schutte J. Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function. Anti-Cancer Drugs. 2002; 13:847-9. 10.1097/00001813-200209000-0001012394270Search in Google Scholar